Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months

Following Activation of the Amyloid Cascade, Apolipoprotein E4 Drives the in vivo Oligomerization of Amyloid-β Resulting in Neurodegeneration

(2017) Haim Belinson et al.   JOURNAL OF ALZHEIMERS DISEASE

Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene

(2017) Jon Valla et al.   JOURNAL OF ALZHEIMERS DISEASE

APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease

(2015) Yen Ying Lim et al.   NEUROBIOLOGY OF AGING

Predicting Alzheimer disease with β-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

(2014) Christopher C. Rowe et al.   ANNALS OF NEUROLOGY

Amyloid and APOE  4 interact to influence short-term decline in preclinical Alzheimer disease

(2014) E. C. Mormino et al.   NEUROLOGY

ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?

(2014) Takahisa Kanekiyo et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The neuropsychology of normal aging and preclinical Alzheimer's disease

(2013) Richard J. Caselli et al.   Alzheimers & Dementia

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease

(2013) Yen Ying Lim et al.   BRAIN

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

(2013) Chia-Chen Liu et al.   Nature Reviews Neurology

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

(2012) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Apolipoprotein E, Not Fibrillar  -Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging

(2012) W. J. Jagust et al.   JOURNAL OF NEUROSCIENCE

Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid   Peptide

(2012) T. Hashimoto et al.   JOURNAL OF NEUROSCIENCE

Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults

(2012) Y. Y. Lim et al.   NEUROLOGY

Amyloid-  assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study

(2012) P. M. Doraiswamy et al.   NEUROLOGY

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

(2011) Victor L. Villemagne et al.   ANNALS OF NEUROLOGY

Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound B

(2009) Martha Storandt et al.   ARCHIVES OF NEUROLOGY

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

(2009) Kathryn A Ellis et al.   INTERNATIONAL PSYCHOGERIATRICS

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Longitudinal Modeling of Age-Related Memory Decline and theAPOEε4 Effect

(2009) Richard J. Caselli et al.   NEW ENGLAND JOURNAL OF MEDICINE

ApoE Promotes the Proteolytic Degradation of Aβ

(2008) Qingguang Jiang et al.   NEURON

Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease

(2008) V.L. Villemagne et al.   NEUROPSYCHOLOGIA